Menu
ncarol.com
  • Home
  • Education
  • Health
  • Books
  • Technology
  • Real Estate
  • Entertainment
  • Music
  • Business
ncarol.com

Aerie Pharmaceuticals to Participate in the Jefferies Healthcare Conference on Friday, June 10, 2022 at 10:30 a.m. ET
ncarol.com/10174876

Trending...
  • CCHR Report Links 145 Violent Incidents to Psychiatric Drug Exposure, Urges National Oversight and Action
  • Outlier Pest Season Hits Willamette Valley as Mild Winter Drives Early Surge in Ant and Rodent Activity
  • Tropidelic Links Up With International Reggae Star Collie Buddz and Eli Mac for Feel-Good Breakthrough Single "Follow Your Nature"
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that Raj Kannan, Chief Executive Officer, along with Peter Lang, Chief Financial Officer, and Dr. Gary Sternberg, Chief Medical Officer, will present at the Jefferies Healthcare Conference on Friday, June 10, 2022 at 10:30 a.m. Eastern Time in New York City, NY.



Date:





June 10, 2022



Presentation Time:





10:30 a.m. ET



Webcast:





http://investors.aeriepharma.com



Replay Availability:





Until September 8, 2022


About Aerie Pharmaceuticals, Inc.

Aerie is a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies for the treatment of patients with eye diseases and conditions including open-angle glaucoma, dry eye, diabetic macular edema (DME) and wet age-related macular degeneration (wet AMD). Aerie's first novel product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain and conjunctival hemorrhage. More information about Rhopressa®, including the product label, is available at www.rhopressa.com. Aerie's second novel product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan® (netarsudil (0.02%) and latanoprost ophthalmic solution (0.005%)), was launched in the United States in May 2019. In clinical trials of Rocklatan®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain and conjunctival hemorrhage. More information about Rocklatan®, including the product label, is available at www.rocklatan.com. More information on Aerie Pharmaceuticals is available at www.aeriepharma.com.

More on ncarol.com
  • Nayarit's Jungle Coast Redefines Luxury Travel on Mexico's Pacific Now More Accessible Than Ever
  • $10 Million Annual Revenue Merger, Profitable Partner in AI Powered Specialty Automotive Sales Projected to Scale Above $200M: Stock Symbol: NWPG
  • Virginia Moving Company Nearly Doubles Customer Calls in Two Weeks After Switching to CARL — the Bold New Alternative to WordPress
  • Crankshooter Names Christian DiMonda Director of Marketing to Lead Brand Growth & Community Strategy
  • RAS AP Consulting Launches Vendor Master File & Payment Controls Assessment for NACHA Phase 2 Compliance

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should," "exploring," "pursuing" or other words that convey the uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements in this release include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, our commercial franchise and our pipeline, any guidance or timelines and our ongoing and anticipated preclinical studies and clinical trials. By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics, industry change and other factors beyond our control, and depend on regulatory approvals and economic and other environmental circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. We discuss many of these risks in greater detail under the heading "Risk Factors" in the quarterly and annual reports that we file with the Securities and Exchange Commission (SEC). Forward-looking statements are not guarantees of future performance and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

More on ncarol.com
  • Living Waters Inc Announces the Passing of Founder and Former President & CEO Lawrence Barker-Bey, Jr
  • New Homesites Released at Heritage at Manalapan Featuring Scenic Golf Course Views
  • The Ultimate Solution to Halt Thermal Runaway
  • Strategic Talent Associates Launches THE ALIGNED RESET™
  • Calvetta Phair Founder & CEO Earns AOPA Foundation Flight Training Scholarship, Inspiring a New Generation of STEM Dreamers in Underserved Communities

Contacts

Media:
Carolyn McAuliffe
cmcauliffe@aeriepharma.com
(949) 526-8733

Investors:
LifeSci Advisors on behalf of Aerie Pharmaceuticals, Inc.
Hans Vitzthum
hans@lifesciadvisors.com
(617) 430-7578
Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on ncarol.com
  • SoPi Rugby's Taco Cook-Off (Cinco de Mayo Weekend)
  • Joseph Neibich sits down with Bold Jounrey (aka Joseph Nybyk)
  • Healing Hearts Home Care Hosts Peace of Mind Community Event
  • AI Suite 360 Launches Done-For-You AI Implementation to Rescue SMBs from the "Frankenstein Tax"
  • CX Network Releases Report on the Best AI Support Tools for SaaS Companies 2026
  • Outlier Pest Season Hits Willamette Valley as Mild Winter Drives Early Surge in Ant and Rodent Activity
  • Hinton Called for Maternal Instincts in AI; They're Ready for Testing with Anthropic's Mythos
  • Lokal Media House Wins Web Excellence Award for Black Plumbing Redesign
  • Charlotte Founder Launches Foot Odor Brand After Years of Embarrassment
  • Lick Expands Flavored Massage Oil Collection with 10 New Indulgent Cream-Inspired Scents
  • New from Regal House Publishing, Local Heroes, Lyric poems exploring themes drawn from ordinary life
  • New Research Identifies "Vacation Compatibility Gap" as the Hidden Force Shrinking How Long and With Whom Americans Travel
  • Melospeech Inc. Awarded New NYSDOH BEI Contract in New York
  • Five-star Review for Berklee School of Music Textbook
  • ZionSphere Launches Multi-Platform Virtual Reality Faith Experience Built from Rocky Mount, NC
  • Rocky Mount Founder Builds Virtual Reality Bible Experiences After Receiving Divine Directive
  • Advanced TeleSensors Appoints AgeTech Innovator Tiffany Wey, MBA as Vice President of Sales & Marketing
  • Daniel Kaufman Real Estate Venture LoneStar Kaufman Development Partners Expands
  • Brian D Chase Selected to the 2026 Nation's Top One Percent Personal Injury Lawyers
  • Most Americans Choose Their Water Brand Because of Its Natural Source — Yet Fewer Than 3 in 10 Understand What Spring Water Actually Is
_catLbl0 _catLbl1

Popular on ncarol.com

  • UK Financial Ltd Launches UKFL Premier One as Its Official Broadcast Channel for Premium Content, Podcasts & Independent Expert Analysis - 112
  • Sycor Introduces Spring Release 2026 of Sycor.Rental with AI-Driven Innovations and Enhanced Service Processes
  • Pacific Emblem Company Launches "Happy 250th Birthday America" Collection and Proud Supporter of the Gary Sinise Foundation
  • Advanced TeleSensors Appoints AgeTech Innovator Tiffany Wey, MBA as Vice President of Sales & Marketing
  • Rhealize Strategic Talent Advisory Co-Founder Dona Baker to Speak at DisruptHR YEG 15.0 in Edmonton on Hiring Innovation
  • Dual-Engine Growth Strategy Unleashed Targeting a $9.1B Market and the Exploding AI Biotech Revolution: KALA BIO (N A S D A Q: KALA)
  • Bold Beauty Project Celebrates Anniversary with Collaborative Exhibition at FIU's Miami Beach Urban Studios
  • PlanetAI Nature Space (PNS), certificadora Europea, lanza su plataforma EUDR-PNS Ready basada en IA, satélites y trazabilidad blockchain
  • UK Financial Ltd Confirms CATEX Exchange Integration of SMPRA and LTNS 1 Ahead of Compliance-Based Trading Activation
  • Most Americans Choose Their Water Brand Because of Its Natural Source — Yet Fewer Than 3 in 10 Understand What Spring Water Actually Is

Similar on ncarol.com

  • $10 Million Annual Revenue Merger, Profitable Partner in AI Powered Specialty Automotive Sales Projected to Scale Above $200M: Stock Symbol: NWPG
  • Virginia Moving Company Nearly Doubles Customer Calls in Two Weeks After Switching to CARL — the Bold New Alternative to WordPress
  • RAS AP Consulting Launches Vendor Master File & Payment Controls Assessment for NACHA Phase 2 Compliance
  • Strategic Talent Associates Launches THE ALIGNED RESET™
  • Calvetta Phair Founder & CEO Earns AOPA Foundation Flight Training Scholarship, Inspiring a New Generation of STEM Dreamers in Underserved Communities
  • 5 Things NYC Courier Services Won't Tell You About How Same-Day Delivery Actually Works
  • AI Suite 360 Launches Done-For-You AI Implementation to Rescue SMBs from the "Frankenstein Tax"
  • CX Network Releases Report on the Best AI Support Tools for SaaS Companies 2026
  • Five-star Review for Berklee School of Music Textbook
  • Unlocking Multi-Sector Growth; Graphite Acquisition Powers EV Entry While Streamlined Consumer Snack Business Fuels Growth: (N A S D A Q: SOWG)
Copyright © 2026 ncarol.com | Contact Us | Privacy Policy | Terms of Service | Contribute